Clinical Trial Update: Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and tolerability of Vitamin E delta-tocotrienol in subjects with resectable pancreatic exocrine neoplasia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neoplasms

Drugs mentioned

• Vitamin E delta-tocotrienol (delta-tocotrienol)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Pancreatic Neoplasms | Phase 1 | Status: COMPLETED